Royalty Pharma plc
RPRX
$60.85
-$1.07-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 16.50% | 10.97% | 4.78% | 7.90% | 7.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.50% | 10.97% | 4.78% | 7.90% | 7.71% |
| Cost of Revenue | 231.52% | -55.33% | -85.91% | 105.33% | -196.00% |
| Gross Profit | -48.13% | 19.08% | 39.40% | -24.63% | 140.92% |
| SG&A Expenses | -32.00% | 40.73% | 180.52% | 108.92% | 370.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.89% | -105.59% | 13.39% | 206.31% | 32.22% |
| Operating Income | -40.78% | 18.40% | -0.76% | -41.75% | -16.63% |
| Income Before Tax | -12.04% | 7.79% | 6.45% | -44.91% | -52.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.04% | 7.79% | 6.45% | -44.91% | -52.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -5.20% | 11.03% | -12.34% | 40.54% | 34.55% |
| Net Income | -44.42% | 23.12% | 2.88% | -47.02% | -68.46% |
| EBIT | -40.78% | 18.40% | -0.76% | -41.75% | -16.63% |
| EBITDA | -40.39% | -- | -- | -- | -- |
| EPS Basic | -47.11% | 22.76% | 9.00% | -45.09% | -66.40% |
| Normalized Basic EPS | -175.39% | 66.76% | -65.88% | -53.68% | -21.91% |
| EPS Diluted | -46.31% | 23.23% | 9.00% | -45.18% | -67.04% |
| Normalized Diluted EPS | -179.90% | 73.68% | -65.88% | -52.66% | -22.08% |
| Average Basic Shares Outstanding | 5.09% | 0.30% | -5.60% | -3.52% | -6.10% |
| Average Diluted Shares Outstanding | -0.96% | -3.68% | -5.60% | -5.59% | -5.80% |
| Dividend Per Share | 6.82% | 6.82% | 4.76% | 4.76% | 4.76% |
| Payout Ratio | 1.02% | -0.11% | -0.02% | 0.91% | 2.11% |